EP
AUPH icon

Eversept Partners’s Aurinia Pharmaceuticals AUPH Stock Holding History

Eversept Partners’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-201,384
Closed -$4.61M – 90
2021
Q4 		$4.61M Buy
+201,384
New +$4.77M 0.29% 65
2021
Q1 		– Sell
-604,368
Closed -$8.36M – 89
2020
Q4 		$8.36M Buy
604,368
+168,373
+39% +$2.45M 0.98% 29
2020
Q3 		$6.42M Sell
435,995
-112,330
-20% -$1.63M 1.43% 22
2020
Q2 		$8.91M Buy
+548,325
New +$8.78M 1.22% 22

Other funds holding AUPH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Eversept Partners's AUPH Position: Q1 2022 in Review

Eversept Partners sold out of Aurinia Pharmaceuticals (AUPH) in Q1 2022, closing a stake of 201,384 shares — an estimated $4.61M sold.

Eversept Partners first reported a position in AUPH in Q2 2020 and held it in 4 quarters. The position peaked at $8.91M in Q2 2020. 184 funds tracked by Wall St. Rank hold AUPH as of Q1 2022.

  • Eversept Partners reported no remaining Aurinia Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Eversept Partners sold 201,384 Aurinia Pharmaceuticals shares in Q1 2022, an estimated $4.61M.
  • Eversept Partners first reported a position in Aurinia Pharmaceuticals in Q2 2020 and held it in 4 quarters.
  • Eversept Partners's Aurinia Pharmaceuticals position peaked at $8.91M in Q2 2020.
  • 184 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2022.

Based on Eversept Partners's 13F filing for Q1 2022, filed 16 May 2022.